Claims for Patent: 10,064,938

Summary for Patent: 10,064,938

Title:	Localized immunosuppression of allografts for peripheral nerve repair
Abstract:	Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient\'s entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.
Inventor(s):	Bushman; Jared (Laramie, WY)
Assignee:	UNIVERSITY OF WYOMING (Laramie, WY)
Application Number:	15/457,359
Patent Claims:	1. A method of peripheral nerve grafting, comprising: delivering a calcineurin inhibitor to a peripheral nerve allograft site in vivo; delivering a glucocorticoid to the peripheral nerve allograft site in vivo; and delivering an immunosuppressive antibody to the peripheral nerve allograft site in vivo, wherein the calcineurin inhibitor, the glucocorticoid, and the immunosuppressive antibody are delivered locally to the peripheral nerve allograft site in vivo by a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein the calcineurin inhibitor is cyclosporine A. 3. The method of claim 1, wherein the calcineurin inhibitor is tacrolimus. 4. The method of claim 1, wherein the glucocorticoid is prednisolone. 5. The method of claim 1, wherein the antibody is selected from the group consisting of ATGAM, visilizumab, alemtuzumab, basiliximab, daclizumab and combinations thereof. 6. The method of claim 1, wherein the pharmaceutically acceptable carrier is a photopolymerizable hydrogel. 7. The method of claim 6, wherein the hydrogel comprises poly(ethylene glycol) diactylate. 8. The method of claim 6, wherein the hydrogel comprises poly(ethylene glycol) norbornene. 9. The method of claim 6, wherein the hydrogel comprises a poly(lactic-co-glycolic acid) material. 10. The method of claim 9, wherein the poly(lactic-co-glycolic acid) material encapsulates the calcineurin inhibitor. 11. The method of claim 9, wherein the poly(lactic-co-glycolic acid) material encapsulates the glucocorticoid. 12. The method of claim 9, wherein the poly(lactic-co-glycolic acid) material encapsulates the immunosuppressive antibody. 13. The method of claim 1, wherein the method further comprises: photopolymerizing the pharmaceutically acceptable carrier in vivo after injecting the pharmaceutically acceptable carrier in the peripheral nerve allograft site. 14. A method of peripheral nerve grafting, comprising: locally delivering in vivo to a peripheral nerve allograft site via a photopolymerizable hydrogel, two or more immunosuppressive agents selected from the group consisting of a calcineurin inhibitor, a glucocorticoid, and an antibody. 15. The method of claim 14, wherein the calcineurin inhibitor is cyclosporine A. 16. The method of claim 14, wherein the calcineurin inhibitor is tacrolimus. 17. The method of claim 14, wherein the glucocorticoid is prednisolone. 18. The method of claim 14, wherein the antibody is selected from the group consisting of ATGAM, visilizumab, alemtuzumab, basiliximab, daclizumab and combinations thereof.

Details for Patent 10,064,938

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Pharmacia & Upjohn Company Llc	ATGAM	lymphocyte immune globulin, anti-thymocyte globulin (equine)	Injection	103676	12/04/1996		2036-03-11
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	05/12/1998		2036-03-11
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	01/02/2003		2036-03-11
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2036-03-11